MacroGenics, Inc. (MGNX)

MacroGenics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	80.36	100.96	108.88	123.47	181.13	126.47
Short-Term Investments	103.88	128.85	45.46	120.15	91.4	89.28
Cash & Cash Equivalents	184.24	229.81	154.35	243.62	272.53	215.76
Cash Growth	-23.76%	48.89%	-36.64%	-10.61%	26.31%	-7.35%
Receivables	7.22	10.37	56.22	10.39	23.08	12.74
Inventory	1.25	1.22	1.45	4.39	0	0
Other Current Assets	9.87	9.95	10.16	21.17	16.98	11.29
Total Current Assets	202.58	251.34	222.18	279.56	312.59	239.79
Property, Plant & Equipment	44.53	45.69	56.91	54.29	42.23	48.21
Other Long-Term Assets	1.19	1.39	1.38	1.4	23.92	24.51
Total Long-Term Assets	45.71	47.08	58.29	55.69	66.15	72.72
Total Assets	248.29	298.42	280.47	335.25	378.74	312.5
Accounts Payable	10.69	6.44	4.9	15.5	8.03	4.31
Deferred Revenue	79.02	80.89	69.47	20.65	11.38	19.85
Current Debt	4.09	3.78	4.73	4.68	3.99	3.02
Other Current Liabilities	-38.03	-35	-30.48	33.76	27.27	17.99
Total Current Liabilities	55.76	56.11	48.61	74.58	50.67	45.17
Long-Term Debt	29.93	30.2	30.11	20.79	25.26	27.55
Other Long-Term Liabilities	56.44	59.5	59.74	0.26	6.93	9.15
Total Long-Term Liabilities	86.37	89.7	89.84	21.05	32.19	36.71
Total Liabilities	142.13	145.81	138.46	95.63	82.86	81.87
Total Debt	34.01	33.97	34.83	25.47	29.25	30.57
Debt Growth	-74.76%	-2.47%	36.77%	-12.92%	-4.33%	-
Retained Earnings	-1,154.94	-1,102.75	-1,093.69	-973.94	-771.82	-642.08
Comprehensive Income	-0.04	-0.01	-0.01	-0.06	-0.01	0.02
Shareholders' Equity	106.15	152.61	142.01	239.62	295.88	230.63
Net Cash / Debt	150.23	195.83	119.51	218.15	243.28	185.18
Net Cash / Debt Growth	40.55%	63.86%	-45.21%	-10.33%	31.37%	-20.48%
Net Cash Per Share	2.41	3.16	1.95	3.64	4.64	3.85
Working Capital	146.81	195.23	173.57	204.98	261.92	194.62
Book Value Per Share	1.70	2.46	2.31	4.00	5.64	4.80

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).